NGLFINENGL Fine-Chem Limited
Pharma · Drug Manufacturers - General · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally. The company offers animal health pharmaceutical ingredients, such as homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, rafoxanide, diminazene aceturate, s-methoprene, carprofen, diminazene diaceturate, ractopamine HCI, toltrazuril, decoquinate, amitraz, marbofloxacin, flunixin meglumine, praziquantel, fenbendazole, and xylazine hydrochloride. It also provides human health pharmaceutical ingredients, including nitazoxanide and atovaquone; and intermediates and specialty chemicals comprising 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-ethyl glucamine. In addition, the company offers finished dosage forms, including diminazene aceturate granules and homidium chloride tablets. NGL Fine-Chem Limited was incorporated in 1981 and is based in Mumbai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on NGLFINE — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Revenue growth: 33.6% YoY
- • Profit growth: 99.1% YoY
- • Debt/Equity: 0.37
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
- • Trend strength (ADX): 29
Bull case
- • Revenue growth: 33.6% YoY
- • Profit growth: 99.1% YoY
- • Debt/Equity: 0.37
- • Price vs SMA200: above
Bear case
- • Dividend yield: 0.06%
- • RSI: 36
- • MACD: bearish
- • 1-month return: -22.6%
Key risks
- • Momentum is fading versus the broader market
- • Dividend yield: 0.06%
- • RSI: 36
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹158.70). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.